Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Plasma Genotyping for Erlotinib in EGFR Mutant NSCLC
NCT02770014Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Started Jun 2016; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02770014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770014.